September 2022 updates to the website

The website has now been updated following September's LSCMMG

The following guidelines have been added/updated:

Asthma desktop guideline - updated

High dose morphine prescribing for chronic non-cancer pain - added

Hydroxychloroquine information sheet - updated

Edoxaban - Choice of DOAC for Stroke Prevention in Non Valvular AF - retired

Testosterone (transdermal) shared care guideline (following July LSCMMG) - added

The following medicines have been updated:

Atectura Breezhaler (indacterol/mometasone) - asthma

Enerzair Breezhaler (glycopyrronium/mometasone/indacterol) - asthma

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Mexiletine - Treatment of documented ventricular arrhythmias which, in the judgement of the physician, are considered as life-threatening.

Vedolizumab - subcutaneous use in gastroenterology indications

Infliximab - subcutaneous use in gastroenterology indications

Risankizumab - treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA803)

Roxadustat - treating symptomatic anaemia in chronic kidney disease (NICE TA807)

Abrocitinib, tralokinumab or upadacitinib - treating moderate to severe atopic dermatitis (NICE TA814)

Guselkumab - treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA815)

Brolucizumab - treating diabetic macular oedema (NICE TA820)